These results indicate that a temporal depletion of CAV1 by lovastatin increases cell surface HER2, which in turn enhances the avidity of HER2-positive tumors for trastuzumab and accelerates tumor uptake of 89Zr-trastuzumab. Here, ERBB2 is linked to neoplasm.